Predictors of noncompliance in patients with schizophrenia

Journal of Clinical Psychiatry

Volumn 63, Issue 12, 2002, Pages 1121-1128

  Perkins, Diana O ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT;

AKATHISIA; AKINESIA; ARTICLE; CARDIOTOXICITY; COST OF ILLNESS; DIABETES MELLITUS; DYSKINESIA; DYSPHORIA; DYSTONIA; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; PARKINSONISM; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RIGIDITY; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SOCIAL PSYCHOLOGY; SOCIAL SUPPORT;

EID: 0036942527     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n1206     Document Type: Article

References (62)

1. Kampman O, Lehtinen K. Compliance in psychoses. Acta Psychiatr Scand 1999;100:167-175
2. Bebbington PE. The content and context of compliance. Int Clin Psychopharmacol 1995;9(suppl 5):41-50
3. Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986; 14:105-122
4. Task Force for Compliance. Non-Compliance With Medications: An Economic Tragedy With Important Implications for Health Care Reform. Baltimore, Md: Task Force for Compliance; 1993
5. Rand CS, Wise RA, Nides M, et al. Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis 1992;146:1559-1564
6. Curson DA, Barnes TR, Bamber RW, et al. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial, 2: the incidence of compliance problems, side-effects, neurotic symptoms and depression. Br J Psychiatry 1985;146:469-474
7. Corrigan PW, Lieberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry 1990;41:1203-1211
8. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;31:67-72
9. Kissling W, Leucht S. Results of treatment of schizophrenia: is the glass half full or half empty? Int Clin Psychopharmacol 1999;14(suppl 3): S11-S14
10. Schooler NR. Maintenance medication for schizophrenia: strategies for dose reduction. Schizophr Bull 1999;17:311-351
11. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-651
12. Van Os J, Wright P, Murray RM. Follow-up studies of schizophrenia, 1: natural history and non-psychopathological predictors of outcome. Eur Psychiatry 1997;12(suppl 5):S327-S341
13. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry 1999;60(suppl 21):25-30
14. Linn MW, Klett CJ, Caffey EM Jr. Relapse of psychiatric patients in foster care. Am J Psychiatry 1982;139:778-783
15. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-247
16. Green JH. Frequent rehospitalization and noncompliance with treatment. Hosp Community Psychiatry 1988;39:963-966
17. Haywood TW, Kravitz HM, Grossman LS, et al. Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995;152:856-861
18. Caton CL, Koh SP, Fleiss JL, et al. Rehospitalization in chronic schizophrenia. J Nerv Ment Dis 1985;173:139-148
19. Helgason L. Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented? Acta Psychiatr Scand 1990;81:231-235
20. Szymanski SR, Cannon TD, Gallacher F, et al. Course of treatment response in first-episode and chronic schizophrenia. Am J Psychiatry 1996;153:519-525
21. Weiden P, Glazer W. Assessment and treatment selection for "revolving door" inpatients with schizophrenia. Psychiatr Q 1997;68:377-392
22. Jeffreys SE, Harvey CA, McNaught AS, et al. The Hampstead Schizophrenia Survey 1991, 1: prevalence and service use comparisons in an inner London health authority, 1986-1991. Br J Psychiatry 1997;170:301-306
23. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994;165(suppl 25):S18-S21
24. Rupp A, Keith SJ. The costs of schizophrenia: assessing the burden. Psychiatr Clin North Am 1993;16:413-423
25. Dencker SJ, Liberman RP. From compliance to collaboration in the treatment of schizophrenia. Int Clin Psychopharmacol 1995;9(suppl 5):75-78
26. Hellewell JSE. Do we know what matters to our patients? Clear Perspectives: Management Issues in Schizophrenia. Approaches to Schizophrenia Communication 1999;2:1-4
27. Janz NK, Becker MH. The Health Belief Model: a decade later. Health Educ Q 1984;11:1-47
28. Agarwal MR, Sharma VK, Kishore Kumar KV, et al. Non-compliance with treatment in patients suffering from schizophrenia: a study to evaluate possible contributing factors. Int J Soc Psychiatry 1998;44:92-106
29. Garavan J, Browne S, Gervin M, et al. Compliance with neuroleptic medication in outpatients with schizophrenia: relationship to subjective response to neuroleptics. Attitudes to medication and insight. Compr Psychiatry 1998;39:215-219
30. Frank AF, Gunderson JG. The role of the therapeutic alliance in the treatment of schizophrenia: relationship to course and outcome. Arch Gen Psychiatry 1990;47:228-236
31. Fleischhacker WW, Meise U, Gunther V, et al. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand 1994;89(supp1382):S11-S15
32. Kissling W, Fleischhacker WW. Optimising prophylactic treatment of schizophrenia by means of treatment standards and compliance improvement. Pharmacopsychiatry 1992;25:69-71
33. Weiden PJ, Mann JJ, Dixon L, et al. Is neuroleptic dysphoria a healthy response? Compr Psychiatry 1989;30:546-552
34. Awad AG, Hogan TP. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand 1994;89(suppl 380):27-32
35. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative ability. Psychol Med 1983;13:177-183
36. Van Putten T, May PRA, Marder SR. Response to antipsychotic medication: the doctor's and the consumer's view. Am J Psychiatry 1984;141: 16-19
37. Gervin M, Browne S, Garavan J, et al. Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology. Eur Psychiatry 1999;14:405-409
38. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992;22:787-797
39. Weiden P, Zygmunt A. Which side-effects really matter to our patients? Clear Perspectives: Management Issues in Schizophrenia. Approaches to Schizophrenia Communication 1999;2:5-11
40. Aizenberg D, Zemishlany Z, Doffman-Etrog P, et al. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry 1995;56:137-141
41. Finn SE, Bailey JM, Schultz RT, et al. Subjective utility ratings of neuroleptics in treating schizophrenia. Psychol Med 1990;20:843-848
42. Buis W. Patients' opinions concerning side effects of depot neuroleptics. Am J Psychiatry 1992;149:844-845
43. Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 1988;153:214-217
44. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982;170:463-467
45. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997;58(suppl 10):45-49
46. Kane JM. What can we achieve by implementing a compliance-improvement program? Int Clin Psychopharmacol 1997;12(suppl 1): S43-S46
47. Dixon L, Weiden P, Torres M, et al. Assertive community treatment and medication compliance in the homeless mentally ill. Am J Psychiatry 1997;154:1302-1304
48. Kemp R. Innovative approaches to improving compliance with antipsychotic treatment. Clear Perspectives: Management Issues in Schizophrenia. Patient Satisfaction, Compliance and Outcomes in Schizophrenia 1999;2:28-31
49. Kemp R, Hayward P, Applewhaite G, et al. Compliance therapy in psychotic patients: randomised controlled trial. BMJ 1996;312:345-349
50. Healey A, Knapp M, Astin J, et al. Cost-effectiveness evaluation of compliance therapy for people with psychosis. Br J Psychiatry 1998;172:420-424
51. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998;32:215-228
52. Knegtering H, Lambers PA, Prakken G, et al. Serum prolactin levels and sexual dysfunctions in antipsychotic medication, such as risperidone: a review. Acta Neurol Psychiatry 2000;12:19-26
53. Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999; 19:57-61
54. Owens DGC. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 1994;55(5, suppl):29-35
55. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233-246
56. Goldstein JM, Arvanitis LA, Cantillon M. Low incidence of reproductive/ hormonal side effects with "Seroquel" (quetiapine fumarate) is supported by its lack of elevation of plasma prolactin concentrations [abstract]. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology; Dec 8-12, 1997; Waikoloa, Hawaii
57. Risperdal [package insert]. Indianapolis, Ind: Eli Lilly & Company; 1999
58. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156: 1686-1696
59. Brecher M, Geller W. Weight gain with risperidone. J Clin Psychopharmacol 1997;17:435-436
60. Westhead EK, Jones AM, Gorman AP. Long-term effect of quetiapine on weight in patients with schizophrenia receiving no concomitant antipsychotic medication [abstract]. Int J Neuropsychopharmacol 2000;3 (suppl 1):147
61. Gaebel W. Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs. Int Clin Psychopharmacol 1997;12(suppl 1):S37-S42
62. Hellewell JS, Kalali AH, Langham SJ, et al. Patient satisfaction and acceptability of long-term treatment with quetiapine. Int J Psychiatry Clin Pract 1999;3:105-113